Your new post is loading...
Learn more about KB001-A study to prevent or treat a common opportunistic gram negative bacterium, Pseudomonas aeruginosa (Pa)
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
KaloBios’ patented proprietary Humaneered® technology platform is designed to address problems of therapeutic antibodies (e.g., specificity, affinity, immunogenicity etc.), as well as equally important downstream processing issues (e.g., solubility, expression, aggregation, etc.). The process is fast and produces antibodies close to human germ-line in sequence while retaining the specificity and improving the affinity of the reference antibody. Humaneered® antibodies have now been tested clinically and to date no anti-drug antibodies have been detected even after dosing healthy human volunteers.
Engineered humanLow/No immunogenicityEqual or higher affinity than starting antibodyFastSolves antibody problems:AggregationStabilityExpression level (in both mammalian and microbial systems)Binding kinetics (select for Ka vs. Kd)This novel system allows a true alternative to classic antibody engineering technologies, bringing a cost advantage to our pipeline as well as the opportunity to provide service to others.